Doubles In 6 Months - Hits 52 Week High

Research Report

This stock has moved from $2.00 to over $4.00 in the past 6 months  recently hiting its 52 week high . This extraordinary drug company is now in the spotlight with its latest super drug  IMP761 -

IMP761 is a humanised IgG4 monoclonal antibody that has been developed by staff in Immutep’s laboratory in Paris.  A patent application has been filed to provide protection for this antibody.

Inflammatory and autoimmune diseases are characterised by activated T cells that react against the patients’ own tissues. They fail to switch off when they should and therefore cause tissue destruction or inflammatory responses. Using an agonist antibody that targets the LAG-3 receptor on the activated T cell is expected to result in an inhibitory signal being delivered directly into the T cell to stop it from continuing to proliferate and react against a patient’s own tissues. 

Serious investors should place this drug company on their BUY LIST

Edison issues update on Immutep (IMMX )

LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Immutep (IMM:ASE) has entered into a clinical trial collaboration and supply agreement with Merck/Pfizer to investigate the combination of its APC activator eftilagimod alpha (efti) with avelumab in patients with advanced solid tumours. Avelumab is the big pharma pair’s investigational anti-PD-L1 immune checkpoint inhibitor (ICI). We view the additional validation from big pharma as a very positive development for Immutep, which could bring the added bonus of early identification of additional target indications. We maintain our valuation at A$510m or A$0.17/share.

Our valuation is unchanged at A$510m, 17c/share (undiluted), or 12c/share after diluting for options and convertible notes. Our valuation includes a modest allowance for expansion of efti indications beyond the ongoing studies in breast, head and neck, melanoma and lung cancers. Gross cash at 30 June was A$23.5m. We assume Immutep will receive a risk-adjusted US$6m IMP731 milestone payment from GSK in FY19, which would extend its cash reach to the end of FY20.  

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

About :
 is a subsidiary of Target Publishing Inc, and is a leading publisher of todays market and investment news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the financial markets and global economies. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications, market exposure and investment. We have been paid cash  for this report . We purchased 100,000 shares of stock in DJI  in Dec 2017

A complete disclaimer can be viewed